The 3rd Annual European NeoAg Summit is the leading industry-dedicated meeting focused on advancing personalised cancer immunotherapy through neoantigen targeting. Over the last year, there has been a record number of neoantigen-based therapies heading into and through the clinic. In addition, exciting collaborations that bring significant investment into the space means that tumour-specific antigen targeting is set to explode. At the European NeoAg Summit, we bring together the leading pharma and biotech companies to discuss: